Design for immuno-oncology clinical trials enrolling both responders and nonresponders

DOI10.1002/SIM.8694zbMATH Open1546.62859MaRDI QIDQ6629846

Zhenzhen Xu, Yongsoek Park, Bin Zhu

Publication date: 30 October 2024

Published in: Statistics in Medicine (Search for Journal in Brave)

zbMATH Keywords

clinical trialproportional hazards assumptioncancer immunotherapydichotomized responseimmuno-oncology trialnonproportional hazards patternsample size and power calculation

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cites Work

• Title not available (Why is that?)
• Maximum likelihood estimation via the ECM algorithm: A general framework
• Weighted Kaplan-Meier Statistics: A Class of Distance Tests for Censored Survival Data
• Estimation in a Cox Proportional Hazards Cure Model

Related Items (1)

M\&M: a maximum duration design with the MaxCombo test for a group sequential trial of an immunotherapy with a random delayed treatment effect

This page was built for publication: Design for immuno-oncology clinical trials enrolling both responders and nonresponders

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6629846)